SCHEMBL4904708

SCHEMBL4904708

CCS(=O)(=O)c1c(-c2ccccc2)nc(N)nc1N1CCOCC1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA2A P29274 3/20 0.49
ADORA1 P30542 3/20 0.49
HSD17B10 Q99714 2/20 0.48
CASP1 P29466 1/20 0.48
NOS1 P29475 1/20 0.47
L3MBTL1 Q9Y468 2/20 0.46
AR P10275 2/20 0.46
ALDH1A1 P00352 3/20 0.45
NUDT1 P36639 1/20 0.44
MTOR P42345 1/20 0.44
MEN1 O00255 2/20 0.44
KMT2A Q03164 2/20 0.44
LMNA P02545 2/20 0.44
MGMT P16455 1/20 0.43
KDM4E B2RXH2 3/20 0.43
TSHR P16473 2/20 0.43
HPGD P15428 1/20 0.43
GAA P10253 1/20 0.43
PDE4A P27815 1/20 0.42
PDE4B Q07343 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Ethylamine SCHEMBL27882003 0.76 ADORA1 (0.60) ADORA2AADORA1HSD17B10CASP1NOS1
SCHEMBL13650807 0.74 NOS1 (0.60) ADORA2AADORA1HSD17B10CASP1NOS1
SCHEMBL6447580 0.73 KDM4E (0.75) ADORA2AADORA1HSD17B10CASP1NOS1
SCHEMBL2323067 0.73 ADORA2A (0.62) ADORA2AADORA1HSD17B10CASP1NOS1
SCHEMBL6133573 0.68 ADORA2A (0.50) ADORA2AADORA1HSD17B10CASP1NOS1
SCHEMBL13650811 0.68 HPGD (0.55) HSD17B10CASP1NOS1ALDH1A1NUDT1
SCHEMBL17942737 0.68 ALDH1A1 (0.67) ADORA2AHSD17B10CASP1ALDH1A1MEN1
SCHEMBL11739114 0.67 KDM4E (0.69) HSD17B10ALDH1A1LMNAKDM4ETSHR
SCHEMBL7708544 0.67 NOS1 (0.58) HSD17B10CASP1NOS1MTORLMNA
SCHEMBL18335242 0.67 DHFR (0.56) ADORA2AADORA1HSD17B10CASP1NOS1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8349859-B2 Pyrimidine derivatives HUTCHISON MEDIPHARMA ENTERPRISES LIMITED (BS) 2013-01-08 US disclosed
US-20080255172-A1 N4-(2-methyl-1H-indol-5-yl)-N2-phenylpyrimidine-2,4-diamine; angiogenesis related disorder like cancer or age-related macular degeneration HUTCHISON MEDIPHARMA ENTERPRISES LIMETED (BS) 2008-10-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080255172-A1 N4-(2-methyl-1H-indol-5-yl)-N2-phenylpyrimidine-2,4-diamine; angiogenesis related disorder like cancer or age-related macular degeneration CCND2, KDR, FLT4 ADORA2A 560/4885ADORA1 680/4885HSD17B10 4511/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.